Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: Results of the GISSI-HF trial

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 7, 2009, Pages 735-748

  Marchioli, Roberto ^a   Levantesi, Giacomo ^a   Silletta, Maria G ^a   Barlera, Simona ^b   Bernardinangeli, Marino ^c   Carbonieri, Emanuele ^d   Cosmi, Francesco ^e   Franzosi, Maria G ^b   Latini, Roberto ^b   Lucci, Donata ^f   Maggioni, Aldo Pietro ^f   Moretti, Luciano ^g   Nicolosi, Gian L ^h   Porcu, Maurizio ⁱ   Rossi, Maria G ^j   Tognoni, Gianni ^a   Tavazzi, Luigi ^k  

^a Consorzio Mario Negri Sud ^*  (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c ASL 4   (Italy)

^d Section of Onco Hematology   (Italy)

^e Cardiologia Ospedale Valdichiana   (Italy)

^f ANMCO RESEARCH CENTER   (Italy)

^g Ospedale Mazzoni   (Italy)

^h S MARIA DEGLI ANGELI HOSPITAL   (Italy)

ⁱ BROTZU HOSPITAL   (Italy)

^j DIVISION OF CARDIOLOGY   (Switzerland)

^k MARIA CECILIA HOSPITAL   (Italy)

more..

Author keywords

Arrhythmia; Heart failure; N 3 polyunsaturated fatty acid; Prognosis; Rosuvastatin; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; OMEGA 3 FATTY ACID; PLACEBO; ROSUVASTATIN; SPIRONOLACTONE; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ARTICLE; BODY MASS; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; HYPERTENSION; MUSCLE DISEASE; QRS COMPLEX; RHABDOMYOLYSIS; SIDE EFFECT; SMOKING; SYSTOLIC BLOOD PRESSURE; AGED; DOUBLE BLIND PROCEDURE; FEMALE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; FEMALE; FLUOROBENZENES; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES; TREATMENT OUTCOME;

EID: 70349316269     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.70     Document Type: Article

References (72)

1. Dickstein K, Cohen-Solal A, Filippatos G et al.; Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J. 29(19), 2388-2442 (2008). ••Reviews the management of heart failure (HF).
2. Albert CM, Campos H, Stampfer MJ et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N. Engl. J. Med. 346, 1113-1118 (2002). ••Methodologically sound paper that relates blood levels of n-3 polyunsaturated fatty acids (PUFA) with the risk of sudden death.
3. Billman GE, Kang JX, Leaf A. Prevention of sudden cardiac death by dietary pure omega-3 polyunsaturated fatty acids in dogs. Circulation 99, 2452-2457 (1999). •Leading paper describing the antiarryhthmic effect of n-3 PUFA in an in vivo canine model of coronary ischemia.
4. Christensen JH, Korup E, Aaroe J et al. Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction. Am. J. Cardiol. 79, 1670-1673 (1997). (Pubitemid 27339480)
5. Curtis BM, O'Keefe JH Jr. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clin. Proc. 77, 45-54 (2002). •Reviews the possible links between autonomic tone and sudden death.
6. Harper CR, Jacobson TA. The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease. Arch. Intern. Med. 161, 2185-2192 (2001).
7. Hu FB, Bronner L, Willett WC et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 287, 1815-1821 (2002).
8. Leaf A. The electrophysiologic basis for the antiarrhythmic and anticonvulsant effects of n-3 polyunsaturated fatty acids: heart and brain. Lipids 36(Suppl.), S107-S110 (2001). •Reviews the evidence on the antiarryhthmic effects of n-3 PUFA.
9. Nordoy A, Marchioli R, Arnesen H, Videbaek J. n-3 polyunsaturated fatty acids and cardiovascular diseases. Lipids 36(Suppl.), S127-S129 (2001).
10. Sellmayer A, Witzgall H, Lorenz RL, Weber PC. Effects of dietary fish oil on ventricular premature complexes. Am. J. Cardiol. 76, 974-977 (1995).
11. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 354, 447-455 (1999). •First large-scale clinical trials showing the benefit of n-3 PUFA in post-myocardial infarction (MI) patients.
12. Marchioli R, Barzi F, Bomba E et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 105, 1897-1903 (2002). •Shows the early effects of n-3 PUFA on sudden death in post-MI patients.
13. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994). •First clinical trial demonstrating the benefit of statins in patients at high risk of coronary heart disease (CHD).
14. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N. Engl. J. Med. 339, 1349-1357 (1998).
15. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
16. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335, 1001-1009 (1996).
17. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109, III39-III43 (2004). •Reviews the pleiotropic effects of statins. (Pubitemid 38786442)
18. Nissen SE. High-dose statins in acute coronary syndromes: not just lipid levels. JAMA 292, 1365-1367 (2004).
19. Dechend R, Fiebeler A, Park JK et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation 104, 576-581 (2001). (Pubitemid 32738128)
20. Drexler H, Hornig B. Endothelial dysfunction in human disease. J. Mol. Cell Cardiol. 31, 51-60 (1999).
21. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc. Res. 47, 648-657 (2000). •Summarizes the evidence on the vascular effects of statins.
22. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 348, 1079-1082 (1996). •Summarizes the evidence on the pleiotropic effects of statins.
23. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372(9645), 1223-1230 (2008). ••Reports the results of GISSI-HF trials on n3-PUFA in HF.
24. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372(9645), 1231-1239 (2008). •Reports the results of the GISSI-HF trials regarding rosuvastatin in HF.
25. Tavazzi L, Tognoni G, Franzosi MG et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur. J. Heart Fail. 6, 635-641 (2004). •Reports the results of the GISSI-HF trials regarding rosuvastatin in HF. (Pubitemid 39070519)
26. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372, 807-816 (2008).
27. Kober L, Torp-Pedersen C, McMurray JJ et al. Increased mortality after dronedarone therapy for severe heart failure. N. Engl. J. Med. 358, 2678-2687 (2008). (Pubitemid 351860860)
28. Konstam MA, Gheorghiade M, Burnett JC Jr et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297, 1319-1331 (2007). (Pubitemid 46513233)
29. Massie BM, Carson PE, McMurray JJ et al. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med. 359, 2456-2467 (2008).
30. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 349, 675-682 (1997).
31. Julian DG, Camm AJ, Frangin G et al. Randomised trial of effect of amiodarone on mortality in patients with leftventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 349, 667-674 (1997).
32. Schwartz PJ, Camm AJ, Frangin G, Janse MJ, Julian DG, Simon P. Does amiodarone reduce sudden death and cardiac mortality after myocardial infarction? The European Myocardial Infarct Amiodarone Trial (EMIAT). Eur. Heart J. 15, 620-624 (1994). (Pubitemid 24186327)
33. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333, 1301-1307 (1995).
34. London B, Albert C, Anderson ME et al. Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office Of Dietary Supplements Omega-3 Fatty Acids and Their Role In Cardiac Arrhythmogenesis Workshop. Circulation 116, E320-E335 (2007). ••Reviews the antiarrhythmic effects of n-3 PUFA.
35. Di Stasi D, Bernasconi R, Marchioli R et al. Early modifications of fatty acid composition in plasma phospholipids, platelets and mononucleates of healthy volunteers after low doses of n-3 polyunsaturated fatty acids. Eur. J. Clin. Pharmacol. 60, 183-190 (2004). •Shows the incorporation in B-cell membranes of n-3 PUFA administered at different dosages.
36. Hibbeln JR, Nieminen LR, Blasbalg TL, Riggs JA, Lands WE. Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. Am. J. Clin. Nutr. 83, 1483S-1493S (2006).
37. Macchia A, Levantesi G, Franzosi MG et al. Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. Eur. J. Heart Fail. 7, 904-909 (2005). •Reports the benefit of n-3 PUFA in post-MI patients according to the level of ejection fraction.
38. Nodari S, Metra M, Milesi G et al. The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. Cardiovasc. Drugs Ther. 23, 5-15 (2009). •Reports on the effects of n-3 PUFA on markers of autonomic tone.
39. Marchioli R, Levantesi G, Macchia A et al. Antiarrhythmic mechanisms of n-3 PUFA and the results of the GISSI-Prevenzione trial. J. Membr. Biol. 206, 117-128 (2005). •Summarizes the results of the GISSI-Prevenzione trial and reviews the possible mechanisms of actions of n-3 PUFA.
40. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 352, 225-237 (2005).
41. Mozaffarian D, Geelen A, Brouwer IA, Geleijnse JM, Zock PL, Katan MB. Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation 112, 1945-1952 (2005). •Meta-analysis summarizing the evidence on the effects of n-3 PUFA heart rate.
42. de Windt LJ, Cox K, Hofstra L, Doevendans PA. Molecular and genetic aspects of cardiac fatty acid homeostasis in health and disease. Eur. Heart J. 23, 774-787 (2002). (Pubitemid 35238491)
43. Endres S, Ghorbani R, Kelley VE et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N. Engl. J. Med. 320, 265-271 (1989). (Pubitemid 19045549)
44. Pepe S, McLennan PL. Dietary fish oil confers direct antiarrhythmic properties on the myocardium of rats. J. Nutr. 126, 34-42 (1996). •One of the first papers suggesting n3-PUFA have antiarrhtyhmic effects in animal models.
45. Pepe S, McLennan PL. Cardiac membrane fatty acid composition modulates myocardial oxygen consumption and postischemic recovery of contractile function. Circulation 105, 2303-2308 (2002). •Shows the effects of n-3 PUFA on cardiac function in ex vivo animal models.
46. Chin JP, Gust AP, Nestel PJ, Dart AM. Marine oils dose-dependently inhibit vasoconstriction of forearm resistance vessels in humans. Hypertension 21, 22-28 (1993).
47. Li Q, Zhang Q, Wang M et al. Docosahexaenoic acid affects endothelial nitric oxide synthase in caveolae. Arch. Biochem. Biophys. 466, 250-259 (2007). (Pubitemid 47451343)
48. Grimsgaard S, Bonaa KH, Hansen JB, Myhre ES. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans. Am. J. Clin. Nutr. 68, 52-59 (1998). (Pubitemid 28307654)
49. Mozaffarian D, Gottdiener JS, Siscovick DS. Intake of tuna or other broiled or baked fish versus fried fish and cardiac structure, function, and hemodynamics. Am. J. Cardiol. 97, 216-222 (2006). (Pubitemid 43139239)
50. Mozaffarian D, Stein PK, Prineas RJ, Siscovick DS. Dietary fish and omega-3 fatty acid consumption and heart rate variability in US adults. Circulation 117, 1130-1137 (2008). (Pubitemid 351544069)
51. Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 357, 2248-2261 (2007). ••Shows the effects of rosuvastatin in patients with systolic HF of iscemic etiology.
52. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362, 759-766 (2003). (Pubitemid 37093915)
53. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat. Rev. 4, 977-987 (2005). •The anti-inflammatory effects of statins.
54. Krum H, Latini R, Maggioni AP et al. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int. J. Cardiol. 119, 48-53 (2007). (Pubitemid 46830817)
55. Levy WC. Observational studies of statins in systolic heart failure. Heart Fail. Clin. 4, 201-208 (2008). •Reviews the evidence of the effect of statins on HF coming from observational studies.
56. de Lemos JA, Blazing MA, Wiviott SD et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292, 1307-1316 (2004).
57. Kastelein JJ, van der Steeg WA, Holme I et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117, 3002-3009 (2008).
58. Khush KK, Waters DD, Bittner V et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 115, 576-583 (2007). (Pubitemid 46226167)
59. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J. Card. Fail. 3, 249-254 (1997).
60. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am. J. Cardiol. 93, 1124-1129 (2004).
61. Scirica BM, Morrow DA, Cannon CP et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J. Am. Coll. Cardiol. 47, 2326-2331 (2006).
62. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J. Am. Coll. Cardiol. 48, 438-445 (2006).
63. Mann DL, McMurray JJ, Packer M et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109, 1594-1602 (2004).
64. Sander S, Coleman CI, Patel AA, Kluger J, White CM. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J. Card. Fail. 12, 464-472 (2006). (Pubitemid 46106977)
65. Sandek A, Bauditz J, Swidsinski A et al. Altered intestinal function in patients with chronic heart failure. J. Am. Coll. Cardiol. 50, 1561-1569 (2007).
66. Fonarow GC. Statins and n-3 fatty acid supplementation in heart failure. Lancet 372(9645), 1195-1996 (2008).
67. Kumar A, Cannon CP. The role of statins in the prevention of heart failure after acute coronary syndrome. Heart Fail. Clin. 4, 129-139 (2008). (Pubitemid 351539136)
68. Hunt SA, Abraham WT, Chin MH et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol. 53, E1-E90 (2009).
69. Yusuf S, Teo K, Anderson C et al.; Telmisartan Randomised AssessmeNt Study in ACE Intolerant subjects with Cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 372(9644), 1174-1183 (2008).
70. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur. Heart J. 27, 2338-2345 (2006). (Pubitemid 44453578)
71. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: the CHARMP-reserved trial. Lancet 362, 777-781 (2003). (Pubitemid 37093918)
72. US NIH Clinical Trials http://clinicaltrials.gov